Shattuck Labs, Inc.
As of Oct 22, 2026, Shattuck Labs is in Stage 3, the topping phase, now in week 4 (since Sep 28, 2026). It closed at $5.60, 30.5% below its 52-week high and below its 200-day average, which is rising.
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is STTK early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
STTK among Biotechnology19th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …19 | STTK | Stage 3 · wk 4 | 98 | −11.9% |
Shattuck Labs: quick answers
What stage is Shattuck Labs in?
As of Oct 22, 2026, Shattuck Labs (STTK) is in Stage 3, the topping phase. It entered Stage 3 on Sep 28, 2026 and is in week 4. What the four stages mean
Is Shattuck Labs in an uptrend?
Its uptrend has stalled. Shattuck Labs is in Stage 3, the topping phase that follows an advance. It trades 6.8% below its 200-day average, which is rising.
How far is Shattuck Labs from its 52-week high?
Shattuck Labs closed at $5.60 on Oct 22, 2026, 30.5% below its 52-week high of $8.06. Its 52-week low is $1.81.
How has Shattuck Labs performed over the past year?
As of Oct 22, 2026, Shattuck Labs is up 191.7% over the past year and up 50.9% so far in 2026.
Which sector and industry is Shattuck Labs in?
Shattuck Labs is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.